← Leaderboards
Stephen Peroutka
Ppd Development Lp
$2,177,956
Attributed
$2,177,956
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,177,956 · 1
By mechanism
N01$2,177,956 · 1
Top collaborators
No co-investigators on record.
Most similar at Ppd Development Lp
Same institution · by research overlap
- Sandra Palleja$722,028
- Matthew Kirkby$20,666,773
- Bambra Strokes$526,656,217
- Kristie Miller$2,791,811
Others in their field
Other Emerging Leaders on “Phase I Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Kimberly Smith · Ppd Development Lp$122,008,792
- Yunda Huang · Fred Hutchinson Cancer Center$73,875,286
- Theresa Engel · Leidos Biomedical Research, Inc.$69,124,785
- Ted Ross · University Of Georgia$68,763,143
Research focus
Phase I Clinical TrialsBasic ScienceBiotechnologyChemistryClinicClinical CandidateClinical ProtocolsClinical TrialsContractorDoseDouble-Blind MethodDrug DevelopmentDrug DiscoveryDrug FormulationsDrug KineticsElementsFundingGrantInstitutionIntellectual PropertyLeadLicensingManufactureMethamphetamine Use Disorder
Grant awards (3)
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS$305,772
N01 · FY2024 · NS · contact PI
IGF::OT::IGF Phase I Clinical Trials for Development of Neurotherapeutics Task Order No. 2 - Petrukin$1,713,940
N01 · FY2019 · NS · contact PI
IGF::OT::IGF Phase I Clinical Trials for Development of Neurotherapeutics Task Order No. 2 - Petrukin$158,244
N01 · FY2018 · DA · contact PI